Gilde Healthcare-backed Synexa Life Sciences completed the acquisition of Syrinx Bioanalytics.

Gilde Healthcare-backed Synexa Life Sciences, a provider of analytical and advisory services, completed the acquisition of Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. Financial terms were not disclosed. "We are delighted to welcome the Syrinx team to the Synexa group and are excited by the opportunities this will bring for our staff and other stakeholders. In particular, we expect the expansion of our scientific capabilities and capacity to have a very positive impact for our biopharma clients, many of whom are developing advanced therapies in the areas such as immunology, immuno-oncology, infectious diseases and targeted radiobiologicals," Paul O’Riordan, Synexa Life Chairman.